BIKTARVY 50 MG
BICTEGRAVIR (BICTEGRAVIR SODIUM) : 50 MG EMTRICITABINE : 200 MG TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) : 25 MG · DIN 02478579 · GILEAD SCIENCES CANADA INC
Health Canada status: MARKETED
What is BIKTARVY?
BIKTARVY 50 MG contains BICTEGRAVIR (BICTEGRAVIR SODIUM) : 50 MG EMTRICITABINE : 200 MG TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02478579, held by GILEAD SCIENCES CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BIKTARVY used for?
BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg with no known substitution associated with resistance to bictegravir or tenofovir.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02478579 |
|---|---|
| Brand name | BIKTARVY |
| Generic / active ingredient | BICTEGRAVIR (BICTEGRAVIR SODIUM) : 50 MG EMTRICITABINE : 200 MG TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) : 25 MG |
| Manufacturer | GILEAD SCIENCES CANADA INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AR20 EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR |
| AHFS class | 24:06.05 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Aug-2018 |
| Original market date | 2018-08-14 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Each bottle contains 7 or 30 tablets. There are 4 blister cards containing 7 tablets and 1 card containing 2 tablets placed inside a paperboard carton for a total of 30 tablets per pack.
What can be used instead?
Other Canadian products sharing ATC code J05AR20 EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BIKTARVY | 10MG | Capsule | GILEAD SCIENCES CANADA INC | MARKETED | DIN 02561492 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.